ArticleSAGE open medicine2026
Comparative analysis of
Article in SAGE open medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fatal Rhinocerebral Mucormycosis andCase reports in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Invasive fungal sinusitis is associated with substantial morbidity and mortality influenced by multiple factors; however, evidence regarding prognostic determinants of survival remains limited. This study aims to evaluate survival outcomes and identify prognostic factors in patients with invasive fungal sinusitis to support evidence-based treatment planning. Methods: A retrospective study was conducted on patients with invasive fungal sinusitis treated between February 2000 and June 2018, with follow-up ending on 30 April 2021. Survival curves were analyzed using the Kaplan-Meier method and log-rank test, while Cox proportional hazards models were employed for univariate and multivariate analyses of prognostic factors. Results: One hundred sixteen patients were diagnosed with invasive fungal sinusitis, and these patients were further classified into an acute sinusitis group (80 patients (69.0%)) and a chronic sinusitis group (36 patients (31.0%)). The overall 1-year survival rate was 49.0% (median survival time of 9.8 months). Among acute invasive fungal sinusitis patients, the 1-year survival rate and median survival time were significantly shorter than those of chronic invasive fungal sinusitis patients. Compared with Conclusions: Invasive fungal sinusitis still has a high mortality rate, particularly in patients with chemosis, altered consciousness and leukopenia, necessitating aggressive treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.